ロード中...
A robust prognostic gene expression signature for early stage lung adenocarcinoma
BACKGROUND: Stage I lung adenocarcinoma is usually not treated with adjuvant chemotherapy; however, around half of these patients do not survive 5 years. Therefore, a reliable prognostic biomarker for early stage patients would be critical to identify those most likely to benefit from early addition...
保存先:
| 出版年: | Biomark Res |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4761211/ https://ncbi.nlm.nih.gov/pubmed/26900477 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-016-0058-3 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|